Please assess the completion status of the following clinical trial:

Trial Title: A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or non-pregnant/non-breast-feeding women of at least 30 years of age at screening.Women of child-bearing potential must be practicing a clinically accepted method of contraception (such as oral contraception, surgical sterilization, intrauterine device \[IUD\], or diaphragm IN ADDITION to spermicidal foam and condom on male partner, or systemic contraception \[i.e. Norplant System\]), during the study and for at least one month prior to randomisation and one month following completion of the study.~* Diagnosis of idiopathic Parkinson's Disease (according to modified Hoehn \& Yahr criteria Stages II-IV) and demonstrating lack of control with L-dopa therapy (e.g. end of dose akinesia, simple on/off fluctuations)~* Subjects receiving a stable dose of L-dopa for at least four weeks prior to screening.~* Provide written informed consent for this study~* A minimum of 3 hours awake timeoff  for each diary day recorded during the Placebo Run-In Period.~* Be willing and able to comply with study procedures, including diary card completion and follow-up clinic visits.~Exclusion Criteria:~* Late stage advanced subjects demonstrating incapacitating peak dose or biphasic dyskinesia on their stable dose of L-dopa.~* Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, hematological, renal, hepatic, endocrinological, neurological (other than Parkinson.s Disease), or cardiovascular disease or active malignancy (other than basal cell cancer);~* Any abnormality, at Screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG;~* Unstable liver disease, cirrhosis, known biliary abnormalities(except Gilbert's syndrome or asymptomatic gallstones) or AST or ALT\>2xULN or alk phos and bilirubin\>1.5 xULN~* Recent history of severe dizziness or fainting due to postural hypotension on standing.~* Clinical dementia that in the judgment of the investigator would preclude assessment of the subject.~* Recent history or current evidence of drug abuse or alcoholism.~* Consumption of any dopamine agonist within four weeks of the screening visit.~* Definite or suspected personal or family history of clinically significant adverse reactions or hypersensitivity to ropinirole (or to drugs with a similar chemical structure) that would preclude long-term dosing with ropinirole PR.~* Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacine, fluvoxamine, cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrolment. Subjects already on chronic therapy with any of these agents may be enrolled but must remain on stable doses of the agent from 7 days prior to enrolment through the end of the Treatment Period.~* Use of an investigational drug within 30 days or 5 half-lives (which ever is longer).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ReQuip PR (Type: EXPERIMENTAL): Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).